Literature DB >> 12947384

The role of the ubiquitin/proteasome system in cellular responses to radiation.

William H McBride1, Keisuke S Iwamoto, Randi Syljuasen, Milena Pervan, Frank Pajonk.   

Abstract

In the last few years, the ubiquitin(Ub)/proteasome system has become increasingly recognized as a controller of numerous physiological processes, including signal transduction, DNA repair, chromosome maintenance, transcriptional activation, cell cycle progression, cell survival, and certain immune cell functions. This is in addition to its more established roles in the removal of misfolded, damaged, and effete proteins. This review examines the role of the Ub/proteasome system in processes underlying the classical effects of irradiation on cells, such as radiation-induced gene expression, DNA repair and chromosome instability, oxidative damage, cell cycle arrest, and cell death. Furthermore, recent evidence suggests that the proteasome is a redox-sensitive target for ionizing radiation and other oxidative stress signals. In other words, the Ub/proteasome system may not simply be a passive player in radiation-induced responses, but may modulate them. The extent of the modulation will be influenced by the functional and structural diversity that is expressed by the system. Cell types vary in the Ub/proteasome structures they possess and the level at which they function, and this changes as they go from the normal to the cancerous condition. Cancer-related functional changes within the Ub/proteasome system may therefore present unique targets for cancer therapy, especially when targeting agents are used in combination with radio- or chemotherapy. The peptide boronic acid compound PS-341, which was designed to inhibit proteasome chymotryptic activity, is in clinical trials for the treatment of solid and hematogenous tumors. It has shown some efficacy on its own and in combination with chemotherapy. Preclinical studies have shown that PS-341 will also potentiate the cytotoxic effects of radiation therapy. In addition, other drugs in common clinical use have been shown to affect proteasome function, and their activities may be valuably reconsidered from this perspective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947384     DOI: 10.1038/sj.onc.1206676

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Isolation and characterization of ubiquitin-activating enzyme E1-domain containing 1, UBE1DC1.

Authors:  Tonghai Dou; Shaohua Gu; Jianping Liu; Fei Chen; Li Zeng; Lingchen Guo; Yi Xie; Yumin Mao
Journal:  Mol Biol Rep       Date:  2005-12       Impact factor: 2.316

2.  Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.

Authors:  Kwanghee Kim; James M Brush; Philip A Watson; Nicholas A Cacalano; Keisuke S Iwamoto; William H McBride
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

3.  Microarray analysis of the gene expression profile in the midgut of silkworm infected with cytoplasmic polyhedrosis virus.

Authors:  Ping Wu; Xiu Wang; Guang-xing Qin; Ting Liu; Yun-Feng Jiang; Mu-Wang Li; Xi-Jie Guo
Journal:  Mol Biol Rep       Date:  2010-03-28       Impact factor: 2.316

Review 4.  Molecular Signaling in Response to Charged Particle Exposures and its Importance in Particle Therapy.

Authors:  Christine E Hellweg; Arif Ali Chishti; Sebastian Diegeler; Luis F Spitta; Bernd Henschenmacher; Christa Baumstark-Khan
Journal:  Int J Part Ther       Date:  2018-09-21

Review 5.  Enhancing radiotherapy through a greater understanding of homologous recombination.

Authors:  Christopher A Barker; Simon N Powell
Journal:  Semin Radiat Oncol       Date:  2010-10       Impact factor: 5.934

6.  Alterations of ubiquitylation and sumoylation in conventional renal cell carcinomas after the Chernobyl accident: a comparison with Spanish cases.

Authors:  Luisa Morell-Quadreny; Alina Romanenko; Jose Antonio Lopez-Guerrero; Silvia Calabuig; Alexander Vozianov; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2011-07-23       Impact factor: 4.064

7.  Human Fas-associated factor 1, interacting with ubiquitinated proteins and valosin-containing protein, is involved in the ubiquitin-proteasome pathway.

Authors:  Eun Joo Song; Seung-Hee Yim; Eunhee Kim; Nam-Soon Kim; Kong-Joo Lee
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Gene interactions in the DNA damage-response pathway identified by genome-wide RNA-interference analysis of synthetic lethality.

Authors:  Gijs van Haaften; Nadine L Vastenhouw; Ellen A A Nollen; Ronald H A Plasterk; Marcel Tijsterman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

9.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Authors:  Kai Sun; Lisbeth A Welniak; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Haiyan Liu; Isabel Barao; William Riordan; Raquel Sitcheran; Christian Wysocki; Jonathan S Serody; Bruce R Blazar; Thomas J Sayers; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

10.  Imaging of radiation effects on cellular 26S proteasome function in situ.

Authors:  James M Brush; Kwanghee Kim; James W Sayre; William H McBride; Keisuke S Iwamoto
Journal:  Int J Radiat Biol       Date:  2009-06       Impact factor: 2.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.